Menlo Park, Calif., and Dallas, Texas, July 8, 2021 —  ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its SORT-LNPTM platform, today announced that CEO and President, David Lockhart, Ph.D., will participate in a panel discussion on non-viral drug delivery at the upcoming William Blair Biotech Focus Conference 2021 at 2:00 pm Eastern Time on Thursday, July 15, 2021.

An archived replay of the presentation will be made available on the Company’s website following the presentation.

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful, proprietary SORT-LNPTM platform to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its SORT-LNPTM and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit and follow us on Twitter @ReCodeTx and LinkedIn.


Media Contact:

Will Zasadny
Canale Communications, Inc.

[email protected]
(619) 961-8848

Investor Contact:

Sarah McCabe

Stern Investor Relations
[email protected]
[email protected]